Product: LPL Antibody
Catalog: BF0636
Description: Mouse monoclonal antibody to LPL
Application: WB ELISA
Reactivity: Human
Mol.Wt.: 53.1kDa; 53kD(Calculated).
Uniprot: P06858
RRID: AB_2833701

View similar products>>

   Size Price Inventory
 50ul $250 In stock
 100ul $350 In stock
 200ul $450 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

ELISA 1:10000, WB 1:500-1:2000
*The optimal dilutions should be determined by the end user.

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Monoclonal [AFB1677]
LPL antibody detects endogenous levels of total LPL.
Cite Format: Affinity Biosciences Cat# BF0636, RRID:AB_2833701.
Mouse IgG1 in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.


EC 3.1.1; EC; HDLCQ11; LIPD; LIPL_HUMAN; Lipoprotein lipase; LPL; LPL protein; MGC137861;



Purified recombinant fragment of human LPL expressed in E. Coli.


Detected in blood plasma (PubMed:2340307, PubMed:11893776, PubMed:12641539). Detected in milk (at protein level) (PubMed:2340307).

LPL: lipoprotein lipase, also known as LIPD, HDLCQ11. Entrez Protein: NP_000228. It is expressed in heart, muscle, and adipose tissue. LPL functions as a homodimer, and has the dual functions of triglyceride hydrolase and ligand/bridging factor for receptor-mediated lipoprotein uptake. Severe mutations that cause LPL deficiency result in type I hyperlipoproteinemia, while less extreme mutations in LPL are linked to many disorders of lipoprotein metabolism.

PTMs - P06858 As Substrate

Site PTM Type Enzyme
S17 Phosphorylation
T19 Phosphorylation
S21 Phosphorylation
K40 Ubiquitination
N70 N-Glycosylation
T75 Phosphorylation
S196 Phosphorylation
K265 Ubiquitination
K299 Ubiquitination
S304 Phosphorylation
Y329 Phosphorylation
Y343 Phosphorylation
N386 N-Glycosylation
K408 Acetylation
T438 Phosphorylation

Research Backgrounds


Key enzyme in triglyceride metabolism. Catalyzes the hydrolysis of triglycerides from circulating chylomicrons and very low density lipoproteins (VLDL), and thereby plays an important role in lipid clearance from the blood stream, lipid utilization and storage. Mediates margination of triglyceride-rich lipoprotein particles in capillaries. Recruited to its site of action on the luminal surface of vascular endothelium by binding to GPIHBP1 and cell surface heparan sulfate proteoglycans.


Tyrosine nitration after lipopolysaccharide (LPS) challenge down-regulates the lipase activity.

Subcellular Location:

Cell membrane>Peripheral membrane protein>Extracellular side. Secreted. Secreted>Extracellular space>Extracellular matrix.
Note: Newly synthesized LPL binds to cell surface heparan proteoglycans and is then released by heparanase. Subsequently, it becomes attached to heparan proteoglycan on endothelial cells (PubMed:27811232). Locates to the plasma membrane of microvilli of hepatocytes with triglyceride-rich lipoproteins (TRL). Some of the bound LPL is then internalized and located inside non-coated endocytic vesicles (By similarity).

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Detected in blood plasma. Detected in milk (at protein level).

Subunit Structure:

Homodimer (Probable). Interacts with GPIHBP1 with 1:1 stoichiometry. Interacts with APOC2; the interaction activates LPL activity in the presence of lipids (By similarity). Interaction with heparan sulfate proteoglycans is required to protect LPL against loss of activity. Associates with lipoprotein particles in blood plasma. Interacts with LMF1 and SEL1L; interaction with SEL1L is required to prevent aggregation of newly synthesized LPL in the endoplasmic reticulum (ER), and for normal export of LPL from the ER to the extracellular space. Interacts with SORL1; SORL1 acts as a sorting receptor, promoting LPL localization to endosomes and later to lysosomes, leading to degradation of newly synthesized LPL.


Belongs to the AB hydrolase superfamily. Lipase family.

Research Fields

· Human Diseases > Neurodegenerative diseases > Alzheimer's disease.

· Metabolism > Lipid metabolism > Glycerolipid metabolism.

· Organismal Systems > Endocrine system > PPAR signaling pathway.

· Organismal Systems > Digestive system > Cholesterol metabolism.

Restrictive clause


Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.